Testosterone-Drug Focused Penny Stock Falls On Bankruptcy Fears

• Clarus Therapeutics Holdings Inc (NASDAQ: CRXT) has implemented a 40% reduction in staff as it evaluates strategic alternatives and terminates certain research and development activities.

• With $19.2 million in cash & cash equivalents and $40.5 million of senior notes payable, the company is pulling out all the stops to stay afloat.

• Clarus also decided to combine the positions of chief financial officer and chief administrative officer. As a result, CFO Richard Peterson will leave the company while CAO Steven Bourne picks up his job.

• The company sells an oral testosterone replacement drug, Jatenzo.

• Management believes the existing cash balance and sales will fund current estimated operating expenses (after implementing headcount reduction) and capital expenditure requirements into September 2022.

• The company noted it might have to stop marketing Jatenzo and file for bankruptcy unless it can restructure its indebtedness and find new capital.

• Robert Dudley, Clarus president & CEO, blames the moves — even as Jatenzo sales have grown — on the challenging financing environment.

• Clarus expects severance and related expenses for the layoffs to add up to $1.1 million.

• Price Action: CRXT shares are down 26.5% at $0.2081 on the last check Friday.

See more from Benzinga

• Bavarian Nordic Recruits US Firm For Packaging Services For Its Monkeypox Vaccine

• Axsome's Depression Candidate Scores FDA Nod, Stock Surges To 52-High

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.